Cullinan Therapeutics (CGEM) Competitors $8.02 -0.27 (-3.26%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$8.02 0.00 (0.00%) As of 03/28/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGEM vs. CGON, HRMY, ARQT, JANX, TVTX, AGIO, TARS, APGE, VERA, and IRONShould you be buying Cullinan Therapeutics stock or one of its competitors? The main competitors of Cullinan Therapeutics include CG Oncology (CGON), Harmony Biosciences (HRMY), Arcutis Biotherapeutics (ARQT), Janux Therapeutics (JANX), Travere Therapeutics (TVTX), Agios Pharmaceuticals (AGIO), Tarsus Pharmaceuticals (TARS), Apogee Therapeutics (APGE), Vera Therapeutics (VERA), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Cullinan Therapeutics vs. CG Oncology Harmony Biosciences Arcutis Biotherapeutics Janux Therapeutics Travere Therapeutics Agios Pharmaceuticals Tarsus Pharmaceuticals Apogee Therapeutics Vera Therapeutics Disc Medicine CG Oncology (NASDAQ:CGON) and Cullinan Therapeutics (NASDAQ:CGEM) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, community ranking, analyst recommendations, dividends, valuation, earnings, media sentiment and risk. Does the MarketBeat Community favor CGON or CGEM? Cullinan Therapeutics received 22 more outperform votes than CG Oncology when rated by MarketBeat users. However, 92.00% of users gave CG Oncology an outperform vote while only 83.33% of users gave Cullinan Therapeutics an outperform vote. CompanyUnderperformOutperformCG OncologyOutperform Votes2392.00% Underperform Votes28.00%Cullinan TherapeuticsOutperform Votes4583.33% Underperform Votes916.67% Which has preferable valuation & earnings, CGON or CGEM? CG Oncology has higher revenue and earnings than Cullinan Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCG Oncology$684K2,937.02-$48.61MN/AN/ACullinan TherapeuticsN/AN/A-$153.16M-$3.03-2.65 Is CGON or CGEM more profitable? Cullinan Therapeutics has a net margin of 0.00% compared to CG Oncology's net margin of -10,642.98%. CG Oncology's return on equity of -18.97% beat Cullinan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CG Oncology-10,642.98% -18.97% -15.36% Cullinan Therapeutics N/A -26.54%-25.32% Does the media favor CGON or CGEM? In the previous week, CG Oncology had 18 more articles in the media than Cullinan Therapeutics. MarketBeat recorded 20 mentions for CG Oncology and 2 mentions for Cullinan Therapeutics. Cullinan Therapeutics' average media sentiment score of 1.77 beat CG Oncology's score of 0.57 indicating that Cullinan Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 3 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Cullinan Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts recommend CGON or CGEM? CG Oncology presently has a consensus target price of $63.88, indicating a potential upside of 141.77%. Cullinan Therapeutics has a consensus target price of $32.86, indicating a potential upside of 309.69%. Given Cullinan Therapeutics' higher probable upside, analysts plainly believe Cullinan Therapeutics is more favorable than CG Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CG Oncology 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Cullinan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, CGON or CGEM? CG Oncology has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Do institutionals and insiders hold more shares of CGON or CGEM? 26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are owned by institutional investors. 6.1% of Cullinan Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryCG Oncology beats Cullinan Therapeutics on 10 of the 16 factors compared between the two stocks. Remove Ads Get Cullinan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGEM vs. The Competition Export to ExcelMetricCullinan TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$469.27M$3.03B$5.64B$7.84BDividend YieldN/A1.55%4.59%4.01%P/E Ratio-2.8229.4223.4718.71Price / SalesN/A431.51388.1890.75Price / CashN/A168.6838.1734.64Price / Book0.763.926.894.23Net Income-$153.16M-$71.95M$3.20B$247.47M7 Day Performance-5.87%-5.68%-3.06%-2.29%1 Month Performance-5.54%-12.09%1.51%-5.81%1 Year Performance-52.93%-27.90%9.35%-0.94% Cullinan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGEMCullinan Therapeutics2.1521 of 5 stars$8.02-3.3%$32.86+309.7%-52.9%$469.27MN/A-2.8230Positive NewsCGONCG Oncology1.1784 of 5 stars$27.67-0.5%$63.88+130.8%-39.8%$2.10B$684,000.000.0061Earnings ReportAnalyst ForecastNews CoverageHigh Trading VolumeHRMYHarmony Biosciences4.4468 of 5 stars$34.32+4.9%$53.11+54.8%-1.2%$1.97B$714.73M16.27200ARQTArcutis Biotherapeutics2.6711 of 5 stars$16.42+12.3%$18.80+14.5%+58.7%$1.95B$196.54M-9.17150Short Interest ↓Positive NewsHigh Trading VolumeJANXJanux Therapeutics2.6185 of 5 stars$31.51+2.7%$92.44+193.4%-22.7%$1.86B$10.59M-26.9330Positive NewsTVTXTravere Therapeutics2.7671 of 5 stars$20.87+5.8%$30.62+46.7%+155.3%$1.85B$233.18M-5.09460News CoveragePositive NewsGap UpAGIOAgios Pharmaceuticals4.3328 of 5 stars$31.99+3.4%$56.57+76.8%+3.6%$1.83B$36.50M2.82390Short Interest ↓Positive NewsTARSTarsus Pharmaceuticals1.8596 of 5 stars$47.49-1.2%$63.67+34.1%+42.3%$1.82B$182.95M-12.4650Insider TradeAPGEApogee Therapeutics2.3846 of 5 stars$40.35+1.0%$92.17+128.4%-40.2%$1.82BN/A-16.6791Positive NewsVERAVera Therapeutics3.0988 of 5 stars$28.07+0.3%$64.67+130.4%-38.2%$1.79BN/A-10.7540Positive NewsIRONDisc Medicine3.1531 of 5 stars$51.27+0.5%$89.10+73.8%-15.9%$1.77BN/A-12.8830Insider TradePositive News Remove Ads Related Companies and Tools Related Companies CGON Alternatives HRMY Alternatives ARQT Alternatives JANX Alternatives TVTX Alternatives AGIO Alternatives TARS Alternatives APGE Alternatives VERA Alternatives IRON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGEM) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cullinan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
